{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:07:57Z","timestamp":1782205677788,"version":"3.54.5"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["11120"],"award-info":[{"award-number":["11120"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,4,21]]},"abstract":"<jats:p>\n            Tedizolid (TZD) and daptomycin (DAP) were assessed in a rat endocarditis model against\n            <jats:named-content content-type=\"genus-species\">Enterococcus faecalis<\/jats:named-content>\n            ,\n            <jats:named-content content-type=\"genus-species\">Enterococcus faecium<\/jats:named-content>\n            (resistant to vancomycin and ampicillin), and\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            . As a monotherapy, TZD for 5 days was not effective in a comparison with no-treatment controls, while DAP for 5 days was significantly effective against these bacteria. Step-down therapy (DAP for 3 days followed by TZD for 2 days) was as effective as DAP for 5 days and was comparable to 3 days of DAP plus ceftriaxone against all bacteria and to 3 days of DAP plus gentamicin against\n            <jats:italic>E. faecalis<\/jats:italic>\n            OG1RF.\n          <\/jats:p>","DOI":"10.1128\/aac.02303-19","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T10:30:12Z","timestamp":1582713012000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Tedizolid as Step-Down Therapy following Daptomycin versus Continuation of Daptomycin against Enterococci and Methicillin- and Vancomycin-Resistant Staphylococcus aureus in a Rat Endocarditis Model"],"prefix":"10.1128","volume":"64","author":[{"given":"Kavindra V.","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"UTHealth Center for Antimicrobial Resistance and Microbial Genomics (CARMiG), Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar A.","family":"Arias","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"Department of Microbiology and Molecular Genetics, University of Texas Medical School at Houston, Houston, Texas, USA"},{"name":"UTHealth Center for Antimicrobial Resistance and Microbial Genomics (CARMiG), Houston, Texas, USA"},{"name":"Center for Infectious Diseases, UTHealth, School of Public Health, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara E.","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA"},{"name":"Department of Microbiology and Molecular Genetics, University of Texas Medical School at Houston, Houston, Texas, USA"},{"name":"UTHealth Center for Antimicrobial Resistance and Microbial Genomics (CARMiG), Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2008.603"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082665"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.24.3022"},{"key":"e_1_3_3_5_2","volume-title":"Enterococci: from commensals to leading causes of drug resistant infection","author":"Agudelo Higuita NI","year":"2014","unstructured":"Agudelo Higuita NI, Huycke MM. 2014. Enterococcal disease, epidemiology, and implications for treatment. In Gilmore MS, Clewell DB, Ike Y, Shankar N (ed), Enterococci: from commensals to leading causes of drug resistant infection. Massachusetts Eye and Ear Infirmary, Boston, MA. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK190429."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0804651"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-014-0431-z"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00742"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16727-5"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808203390806"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.8b01072"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.14193"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00790-19"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02303"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303359"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.241"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-2100-3"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-7-r110"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.175.16.5216-5223.1993"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02627-18"},{"key":"e_1_3_3_21_2","volume-title":"Performance standard for antimicrobial susceptibility testing; 24th informational supplement","author":"CLSI","year":"2019","unstructured":"CLSI. 2019. Performance standard for antimicrobial susceptibility testing; 24th informational supplement. CLSI M100-ED29. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00315-18"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01158-18"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00856-13"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00324-17"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02489-16"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a118408"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01248-16"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00226-10"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00208-09"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.36.9.1864"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.37.2.207"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00101-18"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04376-14"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1458"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit052"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.002431"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku113"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.36.5.907"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg360"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1086\/367661"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00797-12"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01586-12"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02303-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02303-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:49:41Z","timestamp":1645480181000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02303-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4,21]]}},"alternative-id":["10.1128\/AAC.02303-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02303-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"2019-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02303-19"}}